



Flexion Therapeutics, Inc.
 Investor Relations Department
 10 Mall Road
 Suite 301
 Burlington, MA 01803
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: FLXN

Last Trade:	24.68
Trade Time:	10:02 AM ET Jan 17, 2018
Change:	-0.36 ▼ (-1.418%)
Day Range	24.54 - 25.37
52-Week Range	16.51 - 32.25
Volume	105,903

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA).

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Jan 8, 2018*
[Flexion Therapeutics Announces Initial Data from Clinical Trial Evaluating Repeat Administration of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\)](#)
- Dec 18, 2017*
[Flexion Therapeutics Enrolls First Patient in Study Evaluating the Pharmacokinetics and Safety of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Osteoarthritis of the Shoulder and Hip](#)
- Dec 13, 2017*
[Flexion Therapeutics Announces Acquisition of Novel, Non-Opioid Asset for Osteoarthritis of the Knee](#)
- Dec 11, 2017*
[Flexion Therapeutics Announces Appointment of Scott Kelley, M.D. as Chief Medical Officer](#)
- Dec 7, 2017*
[Flexion Therapeutics Enrolls First Patient in Phase 2 Pharmacokinetics and Safety Study of ZILRETTA™ \(triamcinolone acetonide extended-release injectable suspension\) in Bilateral Osteoarthritis of the Knee](#)

Financials [\[View all \]](#)

- [Third Quarter Financial Results](#)
- Mar 10, 2017*
[Annual Report \(10-K\)](#)
- Apr 28, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Nov 6, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 5, 2017*
[Quarterly Report \(10-Q\)](#)

